Clinical Trial Update: To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TG-2349 in combination with DAG181 (± ribavirin) for efficacy and safety in hepatitis C genotype 1 non-cirrhotic patients; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• DAG181
• Ribavirin (ribavirin)
• TG-2349

Snippet

Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Conditions: Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 2 | Status: COMPLETED